Biodexa Pharmaceuticals PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Biodexa Pharmaceuticals Plc's American Depositary Shares.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Biodexa Pharmaceuticals Plc's American Depositary Shares.
NASDAQ
Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have disclosed a 9.9% beneficial ownership stake in Biodexa Pharmaceuticals Plc.
NASDAQ
SCHEDULE 13G/A: Cavalry Funds Divest Biodexa Pharmaceuticals Stake
Multiple investment funds and individuals, including Cavalry Fund I LP and Mercer Street Global Opportunity Fund, LLC, have reported 0% beneficial ownership in Biodexa Pharmaceuticals Plc.
NASDAQ
A group of investment entities and individuals, including Cavalry Fund I LP and Mercer Street Global Opportunity Fund, LLC, have disclosed beneficial ownership of up to 6.8% of Biodexa Pharmaceuticals Plc's Ordinary Shares.
NASDAQ
SCHEDULE 13G: C/M Capital Funds Report 0% Stake in Biodexa Pharmaceuticals Plc, Indicating Significant Divestment
C/M Capital Master Fund, LP and its affiliates, including Thomas Walsh and Jonathan Juchno, have filed a Schedule 13G indicating they no longer hold a beneficial ownership stake in Biodexa Pharmaceuticals Plc, reporting 0% ownership.